On Feb. 25, 2021, Chimerix reported topline results from the first cohort of its randomized, double-blind, placebo-controlled Phase 2/3 study in hospitalized patients with Acute Lung Injury (ALI) and COVID-19 infection.

The primary endpoint of the study was survival without the need for mechanical ventilation through day 28. The first cohort enrolled 12 patients randomized 1:1. One patient on DSTAT was ventilated and recovered. Two patients on placebo progressed to ventilation and died, one on day two and the other post day 28. No deaths were reported in patients on the DSTAT arm.